CLINICAL_TRIALS
trial_result
· 2016-04-08
Clinical Trial Update: Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis [Phase 1, Phase 2]
Summary
Phase 1/2 study of an AAV-RPE65 gene therapy for Leber congenital amaurosis completed, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Beacon Therapeutics | Conditions: Leber Congenital Amaurosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-04-08